MorphoSys AG has broadened its portfolio of oncology assets with an agreement to in-license a candidate bispecific antibody targeting prostate cancer, one of the most common cancers in men. The deal, with Emergent BioSolutions Inc of the US, involves the co-development and commercialisation of a preclinical asset that has shown potential to activate T cell immunity against prostate cancer cells expressing prostate specific membrane antigen.
